STOCK TITAN

RPRX insider plans 69,582-share sale (NASDAQ: RPRX)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

A holder of the issuer’s common stock has filed a Form 144 notice to sell 69,582 shares of common stock through Goldman Sachs & Co. LLC, with an aggregate market value of $2,719,960.38. The filing notes that there were 427,247,489 shares of this class outstanding and that the approximate sale date is January 20, 2026 on the NASD.

The shares to be sold were originally acquired from the issuer in 2020, including 65,832 shares in a private transaction on June 16, 2020 and 3,750 shares as compensation performance awards on February 12, 2020. The notice also lists prior sales over the past three months by entities such as TPC RP 2021 LLC and TPC RP EPA1 LLC, including blocks of 32,916 shares of common stock on various dates, with single transactions generating gross proceeds such as $1,277,555.54.

Positive

  • None.

Negative

  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does this Form 144 filing related to RPRX disclose?

The Form 144 discloses a planned sale of 69,582 shares of common stock of the issuer of RPRX, with an aggregate market value of $2,719,960.38, to be sold through Goldman Sachs & Co. LLC on or about January 20, 2026.

How many RPRX shares are planned to be sold and on which market?

The notice covers a proposed sale of 69,582 shares of common stock to be sold on the NASD, using Goldman Sachs & Co. LLC as broker.

How does the planned RPRX share sale compare to total shares outstanding?

The Form 144 states that 427,247,489 shares of the issuer’s common stock were outstanding, compared with the planned sale of 69,582 shares covered by this notice.

When and how were the RPRX shares in this Form 144 originally acquired?

The filing shows the shares were acquired from the issuer in 2020: 65,832 shares in a private transaction on June 16, 2020 and 3,750 shares as compensation performance awards on February 12, 2020.

What prior RPRX stock sales are reported in the last three months?

The notice lists multiple prior sales of common stock by TPC RP 2021 LLC and TPC RP EPA1 LLC during the past three months, including transactions where 32,916 shares were sold on individual dates with gross proceeds such as $1,277,555.54.

Who is the broker handling the planned RPRX share sale in this Form 144?

The proposed sale of 69,582 shares of common stock is to be executed through Goldman Sachs & Co. LLC, located at 200 West Street, New York, NY 10282.

Royalty Pharma Plc

NASDAQ:RPRX

RPRX Rankings

RPRX Latest News

RPRX Latest SEC Filings

RPRX Stock Data

17.14B
387.98M
8.74%
82.44%
3.85%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW YORK